title: A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes.
abstract: BACKGROUND
  Continuous glucose monitoring (CGM) is a tool widely used in the treatment of patients with type 1 diabetes. The purpose of the current study was to evaluate whether accuracy and patient treatment satisfaction differ between the Enlite™ (Medtronic MiniMed, Inc., Northridge, CA) and Dexcom(®) (San Diego, CA) G4 PLATINUM CGM sensors.
  
  
  METHODS
  Thirty-eight ambulatory patients with type 1 diabetes used the Dexcom G4 and Enlite sensors simultaneously for a minimum of 4 and maximum of 6 days. Patients measured capillary glucose levels with a HemoCue(®) (Ängelholm, Sweden) system six to 10 times a day. In addition, two inpatient studies were performed between Days 1-3 and 4-6.
  
  
  RESULTS
  The mean absolute relative difference (MARD) in blood glucose for the Dexcom G4 was significantly lower (13.9%) than for the Enlite sensor (17.8%) (P<0.0001). The corresponding MARDs for Days 1-3 were 15.0% versus 19.4% (P=0.0027) and 13.6% versus 15.9% (P=0.026) for Days 4-6. For glucose levels in the hypoglycemic range (<4.0 mmol/L), the MARD for the Dexcom G4 was 20.0% compared with 34.7% for the Enlite (P=0.0041). On a visual analog scale (VAS) (0-100), patients rated the Dexcom G4 more favorably than the Enlite in 12 out of the 13 user experience questions. For example, more patients rated their experience with the Dexcom G4 as positive (VAS, 79.7 vs. 46.6; P<0.0001) and preferred to use it in their daily lives (VAS, 79.1 vs. 42.1; P<0.0001).
  
  
  CONCLUSIONS
  The Dexcom G4 sensor was associated with greater overall accuracy than the Enlite sensor during initial (Days 1-3) and later (Days 4-6) use and for glucose levels in the hypoglycemic range. Patients reported a significantly more positive experience using the Dexcom G4 than the Enlite.
authors.affiliation: 1 Institute of Medicine, University of Gothenburg , Gothenburg, Sweden .
authors.forename: Viktorija
authors.initials: V
authors.lastname: Matuleviciene
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Joseph
authors.forename: Mervi
authors.initials: M
authors.lastname: Andelin
authors.forename: Irl B
authors.initials: IB
authors.lastname: Hirsch
authors.forename: Stig
authors.initials: S
authors.lastname: Attvall
authors.forename: Aldina
authors.initials: A
authors.lastname: Pivodic
authors.forename: Sofia
authors.initials: S
authors.lastname: Dahlqvist
authors.forename: David
authors.initials: D
authors.lastname: Klonoff
authors.forename: Börje
authors.initials: B
authors.lastname: Haraldsson
authors.forename: Marcus
authors.initials: M
authors.lastname: Lind
mesh_terms: D000328:Adult; D000368:Aged; D015374:Biosensing Techniques / Q000295:instrumentation; D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D008297:Male; D008422:Materials Testing; D008875:Middle Aged; D018670:Monitoring, Ambulatory; D017060:Patient Satisfaction; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013548:Sweden
chemical_list: D001786:Blood Glucose